Skip to main content
. 2024 Sep 3;68(10):e00562-24. doi: 10.1128/aac.00562-24

Fig 1.

Fig 1

Design of cysteine protease inhibitors. (A) Tripeptide-based interleukin-1β converting enzyme inhibitor. (B) Pfizer coronavirus main protease lead compound reported in WO2005113580. (C) The hydroxymethyl ketone Pfizer lead compound, PF-00835231.